Keywords: جهش راننده; CCA; Cholangiocarcinoma; iCCA; Intrahepatic CCA; pCCA; Perihilar CCA; dCCA; Distal CCA; CDK; Cyclin dependent kinase; CDKN2A/B; Cyclin-dependent kinase inhibitor 2A/B; PLK2; Polo-like kinase 2; FGF; Fibroblast growth factor; HGF; Hepatocyte growth factor;
مقالات ISI جهش راننده (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: جهش راننده; NSCLC; non-small-cell lung cancer; PDX; patient-derived xenograft model; ALK; anaplastic lymphoma kinase; YHIM; Yonsei Human In Mouse; MAF; mutant allele frequency; H&E; hematoxylin and eosin; Non-small-cell lung cancer; Patient-derived xenograft; Preclin
Keywords: جهش راننده; Bone cancer; Osteosarcoma; Genomic analysis; Driver mutations; Animal modeling; Targeted therapy;
Keywords: جهش راننده; NSCLC; ROS1; RET; NTRK; MET; BRAF; KRAS; Driver mutations;
Keywords: جهش راننده; Multiple primary lung cancer; Staging; Driver mutations; Intrapulmonary metastasis;
Keywords: جهش راننده; Driver mutations; Next-generation sequencing; Oncogenic drivers; Precision/personalized medicine; Targeted therapy; Immunotherapy;
Keywords: جهش راننده; Lung adenocarcinoma; Micropapillary pattern; Driver mutations; Prognosis
Keywords: جهش راننده; Driver mutations; Molecular epidemiology; Never-smokers; Non-small-cell lung cancer; Smokers;
Analysis of the proliferative activity in lung adenocarcinomas with specific driver mutations
Keywords: جهش راننده; Immunohistochemistry; Ki-67; Proliferation; Adenocarcinoma; Non-small cell lung cancer; NSCLC; Digital image analysis; Driver Mutations; Lung cancer; Pathology;
A Prospective Blinded Evaluation of Urine-DNA Testing for Detection of Urothelial Bladder Carcinoma in Patients with Gross Hematuria
Keywords: جهش راننده; Bladder cancer; Urothelial carcinoma; Driver mutations; Noninvasive detection; Urinary biomarkers; DNA methylation; Urine filtration; Droplet digital PCR;
Diagnostic algorithm for detection of targetable driver mutations in lung adenocarcinomas: Comprehensive analyses of 205 cases with immunohistochemistry, real-time PCR and fluorescence in situ hybridization methods
Keywords: جهش راننده; Lung adenocarcinoma; Molecular testing; Immunohistochemistry; Driver mutations;
BRAF V600E mutations: a series of case reports in patients with non–small cell lung cancer
Keywords: جهش راننده; BRAF; non-small cell lung cancer; driver mutations; V600E; adenocarcinoma
Profiling of Oncogenic Driver Events in Lung Adenocarcinoma Revealed MET Mutation as Independent Prognostic Factor
Keywords: جهش راننده; Lung cancer; EGFR; KRAS; ALK; HER2; BRAF; MET; ROS1; RIT1; TTF-1 lung adenocarcinoma; NRAS; Driver mutations; Oncogenic driver mutation; East Asian lung cancer; MET amplification; Targeted therapy; Genetic marker; Biomarker; Molecular classification lung
Driver mutations among never smoking female lung cancer tissues in China identify unique EGFR and KRAS mutation pattern associated with household coal burning
Keywords: جهش راننده; EGFR; KRAS; Lung cancer; Never smoking; China; Driver mutations;
Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose
Keywords: جهش راننده; Lung adenocarcinoma; Smokers; Driver mutations
Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): A better mousetrap? A review of the clinical evidence
Keywords: جهش راننده; Afatinib (BIBW 2992); Erlotinib; Gefitinib; Dacomitinib (PF-00299804); Non-small cell lung cancer; Epidermal growth factor receptor (EGFR) mutations; Driver mutations; Human epidermal growth factor receptor 2 (HER2); Exon 20 insertion mutations